Business Venturing in Regulated Markets—Taxonomy and Archetypes of Digital Health Business Models in the European Union: Mixed Methods Descriptive and Exploratory Study by Sascha Noel Weimar, Rahel Sophie Martjan, Orestis Terzidis

“…In addition, 6 archetypes of DHT business models were identified: administration and communication supporter (A1), insurer-to-consumer digital therapeutics and care (A2), diagnostic and treatment enabler (A3), professional monitoring platforms (A4), clinical research and solution accelerators (A5), and direct-to-consumer wellness and lifestyle (A6). …”
Get full text

Exploring seasonal dynamics of sea spray aerosol bioactivity: Insights into molecular effects on human bronchial epithelial cells by Zixia Liu, Emmanuel Van Acker, Maarten De Rijcke, Filip Van Nieuwerburgh, Colin Janssen, Jana Asselman

“…We provide novel insights into the molecular effects of SSA exposure and highlight its potential as a source of natural therapeutics. To our knowledge, this is the first study to expose human lung cells to natural SSA at environmentally relevant levels, presenting a pioneering exploration of seasonal variations in exposure effects.…”
Get full text

Characterising COVID-19 empirical research production in Latin America and the Caribbean: A scoping review. by Cristián Mansilla, Cristian A Herrera, Laura Boeira, Andrea Yearwood, Analia S Lopez, Luis E Colunga-Lozano, Eva Brocard, Tatiana Villacres, Marcela Vélez, Gabriel Di Paolantonio, Ludovic Reveiz

“…Using a modified version of WHO's COVID-19 Coordinated Global Research Roadmap classification, 54.2% were epidemiological studies, followed by clinical management (22.3%) and candidate therapeutics (12.2%). Government and public funds support were reported in 19.2% of studies, followed by universities or research centres (9%), but 47.5% did not include any funding statement.…”
Get full text

Novel inhibitors of the (VIBVN) NAT protein identified through pharmacophore modeling by Wei Wei, Xionghao Li, Ning Hou, Aowei Xie, Huicong Liang, Ting Gao, Xiaoli Jing, Liqin Li, Jiejie Hao, Ximing Xu

“…Our findings provide a valuable foundation for the future development of drugs targeted therapeutics against (VIBVN)NAT.…”
Get full text

Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs by María Sancho-Albero, Alessandra Decio, Reha Akpinar, Ada De Luigi, Raffaella Giavazzi, Luigi M. Terracciano, Luisa De Cola

“…Despite the use of targeting units such as antibodies, peptides and proteins to increase their penetration in tumors the amount of therapeutics that reach the target is very small, even with the use of nanoparticles (NPs). …”
Get full text

Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers by Bill Liao, Christine Tumanut, Lin Li, Adam Corper, Dilip Challa, Alex Chang, Hydari Begum, Elinaz Farokhi, Catherine Woods, Xiaomin Fan

“…These anti-CD16a antibody clones are promising candidates for combination with any TAA of interest, offering the potential for novel NK cell engager-based cancer therapeutics that are minimally affected by the high concentrations of human IgG in the circulation.…”
Get full text

Cell Therapy for Refractory Angina: A Reappraisal by Beatrice Bassetti, Patrizia Nigro, Valentina Catto, Laura Cavallotti, Stefano Righetti, Felice Achilli, Paolo Scacciatella, Corrado Carbucicchio, Giulio Pompilio

“…Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). …”
Get full text

Feature selection enhances peptide binding predictions for TCR-specific interactions by Hamid Teimouri, Hamid Teimouri, Zahra S. Ghoreyshi, Zahra S. Ghoreyshi, Anatoly B. Kolomeisky, Anatoly B. Kolomeisky, Anatoly B. Kolomeisky, Jason T. George, Jason T. George, Jason T. George, Jason T. George

“…The results of our feature selection method are consistent with findings from hybrid approaches that utilize both sequence and structural data as input as well as experimental data.DiscussionOur theoretical approach highlights the role of feature selection in peptide-TCR interactions, providing a quantitative tool for uncovering the molecular mechanisms of the T-cell response and assisting in the design of more advanced targeted therapeutics.…”
Get full text

Preconception Care Uptake and Immediate Outcomes among Discordant Couples Accessing Routine HIV Care in Kenya by Nyawira Gitahi, Sheila Juliet Eshiwani, Kenneth Mutai, Jared Ongechi Mecha, James Njogu Kiarie

Get full text

Molecular dynamics and machine learning unlock possibilities in beauty design—A perspective by Yuzhi Xu, Haowei Ni, Fanyu Zhao, Qinhui Gao, Ziqing Zhao, Chia-Hua Chang, Yanran Huo, Shiyu Hu, Yike Zhang, Radu Grovu, Hermione He, John Z. H. Zhang, Yuanqing Wang

“…Computational molecular design—the endeavor to design molecules, with various missions, aided by machine learning and molecular dynamics approaches—has been widely applied to create valuable new molecular entities, from small molecule therapeutics to protein biologics. In the small data regime, physics-based approaches model the interaction between the molecule being designed and proteins of key physiological functions, providing structural insights into the mechanism. …”
Get full text

Single-cell RNA-sequencing and genome-wide Mendelian randomisation along with abundant machine learning methods identify a novel B cells signature in gastric cancer by Qi Ma, Jie Gao, Yuan Hui, Zhi-Ming Zhang, Yu-Jie Qiao, Bin-Feng Yang, Ting Gong, Duo-Ming Zhao, Bang-Rong Huang

“…NFKBIE may function as a novel biomarker and therapeutic target for GC.…”
Get full text

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease by Brandon Zimmerman, Leslie A. Dakin, Anne Fortier, Evanthia Nanou, Angelo Blasio, James Mann, Howard Miller, Marissa Fletcher, Tiansheng Wang, Suganthini Nanthakumar, Gizelle McCarthy, Caline Matar, Prachi Matsye, Guanyu Wang, Phillip Snyder, Kevin Daniel, Harsha Swamy, Kelly Sullivan, Franklin Bright, Audrey Powers, Kevin J. Gagnon, Fan Lu, Steven Paula, Suvarna Khare-Pandit, Larry Henry, Martine Hamel, Francois Denis, Olivier Nicolas, Niresh Hariparsad, Shyamesh Kumar, Jennifer Proctor, Timothy Senter, Brinley Furey, Mark E. Bunnage

“…Abstract Chronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. …”
Get full text

Diospyros mespilifoemis hochst Modulates the Hippocampus and Prefrontal Cortex of Wistar Rat following Lithium chloride pilocarpine-induced Epilepsy by Sunday Yinka Olatunji, Oluwafemi Ezekiel Kale, Oluseyi Abimbola Ogunsola, John Afees Olanrewaju, Ijeoma Esiaba, Taiye Adelodun, Olubunmi Philip Ogunnaike

Get full text

Engineered Perfluorochemical Cancer-Derived Exosomes Loaded with Indocyanine Green and Camptothecin Provide Targeted Photochemotherapy for Effective Cancer Treatment by Lee YH, Huang CY

“…Yu-Hsiang Lee,1– 3 Cheng-You Huang1 1Department of Biomedical Sciences and Engineering, National Central University, Taoyuan City, Taiwan, Republic of China; 2Department of Chemical and Materials Engineering, National Central University, Taoyuan City, Taiwan, Republic of China; 3Department of Medical Research, Cathay General Hospital, Taipei City, Taiwan, Republic of ChinaCorrespondence: Yu-Hsiang Lee, Department of Biomedical Sciences and Engineering, National Central University, No. 300, Jhongda Road, Taoyuan City, 320317, Taiwan, Republic of China, Tel +886-3-422-7151 Ext# 27755, Fax +886-3-280-4627, Email yuhsianl@ncu.edu.twBackground: Cancer treatments are still limited by various challenges, such as off-target drug delivery, posttreatment inflammation, and the hypoxic conditions in the tumor microenvironment; thus, the development of effective therapeutics remains highly desirable. Exosomes are extracellular vesicles with a size of 30– 200 nm that have been widely applied as drug carriers over the last decade. …”
Get full text

Inhibition of Aβ Aggregation by Cholesterol-End-Modified PEG Vesicles and Micelles by Shota Watanabe, Motoki Ueda, Shoichiro Asayama

“…Chol-PEG assemblies can deliver additional therapeutics targeting other aspects of AD pathology. …”
Get full text

Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement by Anas H. A. Abu-Humaidan, Fatima M. Ahmad, Dima Awajan, Raba’a F. Jarrar, Nader Alaridah

Get full text

Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction by Pasquale Tondo, Giulia Scioscia, Cosimo C. De Pace, Fabiola Murgolo, Federica Maci, Giulia M. Stella, Dalila Pescatore, Maria Pia Foschino Barbaro, Donato Lacedonia

Get full text

SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsResearch in context by Moreno Ursino, Guillermo Villacampa, Jan Rekowski, Munyaradzi Dimairo, Olga Solovyeva, Deborah Ashby, Jordan Berlin, Oliver Boix, Melanie Calvert, An-Wen Chan, Courtney H. Coschi, Thomas R. Jeffry Evans, Elizabeth Garrett-Mayer, Robert M. Golub, Christina Guo, Kathryn S. Hayward, Sally Hopewell, John D. Isaacs, S. Percy Ivy, Thomas Jaki, Olga Kholmanskikh, Andrew Kightley, Shing Lee, Rong Liu, Adrian Mander, Lynley V. Marshall, James Matcham, Dhrusti Patel, Richard Peck, Khadija Rerhou Rantell, Dawn P. Richards, Mahtab Rouhifard, Lesley Seymour, Yoshiya Tanaka, Christopher J. Weir, Johann de Bono, Christina Yap

“…Each new or modified checklist item is accompanied by a detailed description, its rationale with supportive evidence, and examples of good reporting curated from EPDF trial protocols covering a range of therapeutic areas and interventions. We recommend utilising this paper alongside the SPIRIT statement, and any relevant extensions, to enhance the development and review of EPDF trial protocols.By facilitating adoption of the SPIRIT-DEFINE statement for EPDF trials, this E&E document can promote enhancement of methodological rigour, patient safety, transparency, and facilitate the generation of high-quality, reproducible evidence that will strengthen the foundation of early phase research and ultimately improve patient outcomes. …”
Get full text

CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsResearch in context by Jan Rekowski, Christina Guo, Olga Solovyeva, Munyaradzi Dimairo, Mahtab Rouhifard, Dhrusti Patel, Emily Alger, Deborah Ashby, Jordan Berlin, Oliver Boix, Melanie Calvert, An-Wen Chan, Courtney H. Coschi, Johann de Bono, Thomas R. Jeffry Evans, Elizabeth Garrett–Mayer, Robert M. Golub, Kathryn S. Hayward, Sally Hopewell, John D. Isaacs, S. Percy Ivy, Thomas Jaki, Olga Kholmanskikh, Andrew Kightley, Shing Lee, Rong Liu, Israel Maia, Adrian Mander, Lynley V. Marshall, James Matcham, Richard Peck, Khadija Rerhou Rantell, Dawn P. Richards, Lesley Seymour, Yoshiya Tanaka, Moreno Ursino, Christopher J. Weir, Christina Yap

“…Comprehensive and transparent reporting of these studies is critical for their accurate and critical interpretation, which may improve and expedite therapeutic development. However, quality of reporting of design characteristics and results from EPDF trials is often variable and incomplete. …”
Get full text

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors by Romain Pacaud, Scott Thomas, Sibapriya Chaudhuri, Ann Lazar, Luika A. Timmerman, Pamela N. Munster

“…Thus we are seeking alternative therapeutics to enhance PARP-directed outcomes. In an effort to expand the clinical use of PARP inhibitors to HRR proficient tumors, several groups have tested combinations of DNA methyltransferase inhibitors and PARP inhibitors. …”
Get full text